The field has moved fast. Not long ago longevity was treated as a curiosity; now Longevity's a real investment category, on track to reach $67B by 2035. That shift is the thing worth paying attention to. The good companies aren't selling immortality. They're going after healthspan, treating aging as a root cause, and measuring themselves against clinical results.

For decades, the luxury skincare industry operated as a high-margin consumer category—a commoditized market built on aesthetic masking. That era has concluded. We are currently witnessing a decisive migration of R&D capital into a new domain: Cellular Longevity. This is not a shift in marketing; it is a fundamental re-engineering of the industry's value chain, moving from cosmetic maintenance to high-barrier biological intervention. The market has bifurcated. On one side,